Search

everythinglearnresearchcommunity

for

Search:↓

SCUBE3, a protein linked to hair growth in moles, was discovered over 25 years ago and is being developed by Amplifica for potential hair loss treatment. Concerns exist about SCUBE3's association with cancer, as it is a protein that promotes cell growth, which could potentially trigger cancer development if used for hair growth therapy.

Skepticism about hair loss research motivations, suggesting financial interests hinder finding a cure. Mentions treatments like minoxidil, finasteride, and dutasteride, but notes they are not cures.

PP405 is considered a promising potential cure for hair loss, with phase 2 trial results expected in February 2025. Hair cloning is also discussed as a potential ultimate solution, despite significant scientific challenges.

Deoxyribose sugar gel may stimulate hair regrowth similarly to minoxidil by enhancing blood supply and follicle activity. Human trials are necessary, and current products have mixed results.

Balding is challenging, and relying on medications like finasteride is often seen as a better option than constantly shaving or trying to compensate in other areas. Many feel that societal expectations to "own it" or drastically change oneself to cope with baldness are unrealistic and burdensome.

PP405 is viewed skeptically, with some seeing it as overhyped and potentially ineffective compared to existing treatments like minoxidil and finasteride. While it shows some promise in activating dormant hair follicles, many believe it won't replace hair transplants or significantly outperform current options.

A 31-year-old man feels depressed due to hair loss, using topical finasteride and previously tried minoxidil. Others suggest treatments like finasteride, minoxidil, hair transplants, or embracing baldness, highlighting the importance of mental health and self-acceptance.

PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.

The conversation discusses various hair growth treatments, including topical and oral minoxidil, microneedling, LLLT, PRP, exosomes, latanoprost, copper peptides, and upcoming treatments like PP405 and Vdphl01. It also covers managing side effects of minoxidil, such as dry scalp, and mentions the use of dutasteride and finasteride for hair loss.

PP405 shows promise in treating severe hair loss, with 31% of users experiencing over 20% hair density increase in four weeks, faster than minoxidil and finasteride. Some users are skeptical about the results' significance and long-term efficacy.

PP405 shows promise for hair follicle reactivation with minimal side effects. Users recommend continuing Minoxidil and Finasteride until more results are confirmed.

_the_orange_box_'s experience using oral minoxidil, with discussion about finasteride and the potential side effects of both treatments. Other users shared their own experiences related to hair loss treatments.

Pelage Pharmaceuticals raised $120M for their hair loss treatment, PP405, showing strong investor confidence despite limited data. There is skepticism about its efficacy and long-term effects compared to treatments like GT20029.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

Hair loss treatments like finasteride, minoxidil, and hair transplants are more accessible and effective now. Concerns about side effects and skepticism about new treatments like hair cloning and GT20029 remain.

GT20029 and KX826 are promising hair loss treatments, with GT20029 increasing hair count and KX826 showing significant results. KX826 may be a good alternative for those who can't use finasteride or dutasteride, though results vary.

Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.

The user experienced hair regrowth using finasteride for 1.5 years and minoxidil foam for 4 months, starting at age 17. They reported no side effects and noted that finasteride helped maintain existing hair while minoxidil contributed to regrowth.

Switching from finasteride to dutasteride worsened hair loss and caused a burning sensation. Users suggest sticking with finasteride, using ketoconazole shampoo, and consulting a dermatologist.

Switching from finasteride to dutasteride and back to finasteride led to gynecomastia and fatigue, likely due to hormonal imbalances. Suggested treatments include Tamoxifen, Raloxifene, or low-dose Anastrozole, with a recommendation to test testosterone and estradiol levels.

Switching from finasteride to dutasteride and back to finasteride, with mixed results on hair loss and side effects like oily skin and acne. Some users experienced regrowth with oral minoxidil, while others noted differences in effectiveness and side effects between the two medications.

The user experienced severe side effects from oral finasteride, including sexual dysfunction and mental health issues, and switched to topical finasteride, which led to significant hair shedding. They are considering other treatments like RU58841 or topical dutasteride and are advised to check testosterone levels and address potential underlying health issues.

Sons are offering free Biotin capsules, Thickening Clay, or Conditioner for hair care testing to UK men. Interested individuals can apply to receive these products without purchase.

A user switched from topical to oral finasteride (0.5mg daily) and continued using topical minoxidil, seeing significant improvement in hair loss over four months. The user is pleased with the results, especially on the crown, and notes that hairline recession has stopped.

A 25-year-old male has been using finasteride and 2.5mg oral minoxidil for 8-10 months and is seeking advice on improving hair growth at the crown. He is considering whether to continue with finasteride or switch to dutasteride.

A 21-year-old is experiencing hair thinning and is considering using oral finasteride and minoxidil. They are seeking advice on the cheapest and easiest provider among Drb.ai, ro.co, or Amazon One Medical.

The user has been using a combination of minoxidil and finasteride for six months, seeing initial improvement in hair thickness at the crown, but recently noticed a regression. It is suggested to continue the treatment for a few more months as fluctuations are common, and consider switching to dutasteride if no improvement occurs.

A 19-year-old is experiencing hereditary hair thinning and is considering switching from topical to oral minoxidil due to convenience and starting finasteride at a low dose to minimize side effects. A suggestion was made to start with 0.25 mg of finasteride daily and gradually increase to 0.5 mg, while oral minoxidil requires a prescription.

A 23-year-old male is experiencing large dandruff flakes causing hair loss, despite using anti-dandruff shampoo. He seeks advice on resolving the issue, noting a family history of baldness.